Treatment of Payments in Lieu of Taxes Under Section 141, 77352 [E6-22017]

Download as PDF mstockstill on PROD1PC61 with PROPOSALS 77352 Federal Register / Vol. 71, No. 247 / Tuesday, December 26, 2006 / Proposed Rules heartburn, upset stomach, or stomach pain [bullet] ulcers [bullet] bleeding problems [bullet] high blood pressure [bullet] heart or kidney disease [bullet] taken a diuretic [bullet] reached age 60 or older’’. (C) The labeling states ‘‘Ask a doctor or pharmacist before use if you are [heading in bold type] [bullet] taking any other drug containing an NSAID (prescription or nonprescription [bullet] taking a blood thinning (anticoagulant) or steroid drug [bullet] under a doctor’s care for any serious condition [bullet] taking any other drug’’. * * * * * (E) In addition to the warning required in § 201.324(c) of this chapter after the subheading ‘‘Stop use and ask a doctor if’’ [heading in bold type], the following statements also appear: ‘‘[bullet] you feel faint, vomit blood, or have bloody or black stools. These are signs of stomach bleeding. [bullet] pain gets worse or lasts more than 10 days [bullet] fever gets worse or lasts more than 3 days [bullet] stomach pain or upset gets worse or lasts [bullet] redness or swelling is present in the painful area [bullet] any new symptoms appear‘‘. * * * * * (2) * * * (i) For products containing any ingredient in § 343.10 (a) through (f) The labeling states ‘‘Stop use and ask a doctor if [heading in bold type] [bullet] pain gets worse or lasts more than 5 days [bullet] fever gets worse or lasts more than 3 days [bullet] redness or swelling is present [bullet] any new symptoms appear ’’. * * * * * (iii) For products containing acetaminophen identified in § 343.10(a). The labeling states the warnings in § 201.325(a)(1)(iv)(A)(1), (a)(1)(iv)(A)(2), and (a)(1)(iv)(A)(3) and the following statement must follow the general warning identified in § 330.1(g) of this chapter: ‘‘Prompt medical attention is critical even if you do not notice any signs or symptoms.’’ (iv) * * * (A) The labeling states the warning in paragraph (c)(2)(v)(B) plus the bulleted statement ‘‘asthma’’. * * * * * (v) * * * (A) The labeling states the warning in paragraph (c)(2)(i) of this section plus ‘‘[bullet] the child feels faint, vomits blood, or has bloody or black stools. These are signs of stomach bleeding. [bullet] stomach pain or upset gets worse or lasts [bullet] ringing in the ears or loss of hearing occurs’’. (B) The labeling states ‘‘Ask a doctor before use if the child has [heading in VerDate Aug<31>2005 13:25 Dec 22, 2006 Jkt 211001 bold type] [bullet] stomach problems that last or come back, such as heartburn, upset stomach, or stomach pain [bullet] ulcers [bullet] bleeding problems [bullet] not been drinking fluids [bullet] lost a lot of fluid due to vomiting or diarrhea [bullet] high blood pressure [bullet] heart or kidney disease [bullet] taken a diuretic’’. (C) The labeling states ‘‘Ask a doctor or pharmacist before use if the child is [heading in bold type] [bullet] taking any other drug containing an NSAID (prescription or nonprescription) [bullet] taking a blood thinning (anticoagulant) or steroid drug [bullet] taking a prescription drug for diabetes, gout, or arthritis’’. * * * * * (3) * * * (i) For products containing any ingredient in § 343.10 (a) through (f). The labeling states ‘‘Stop use and ask a doctor if [heading in bold type] [bullet] adult’s pain gets worse or lasts more than 10 days [bullet] child’s pain gets worse or lasts more than 5 days [bullet] fever gets worse or lasts more than 3 days [bullet] redness or swelling is present [bullet] any new symptoms appear’’. (ii) The warning in § 343.50(c)(1)(ii), if applicable. (iii) For products containing acetaminophen identified in § 343.10(a). The labeling states the warnings in § 201.325(a)(1)(v) of this chapter. The warning in § 201.325 (a)(1)(v)(B) is modified to read: ‘‘ Ask a doctor before use if the user [heading in bold type] [bullet] has liver disease [bullet] is a child with pain of arthritis’’. The following statement must follow the general warning identified in § 330.1(g) of this chapter: ‘‘Prompt medical attention is critical for adults as well as for children even if you do not notice any signs or symptoms.’’ (iv) The warnings in § 343.50(c)(1)(iv), if applicable. (v) For products containing aspirin, carbaspirin calcium, choline salicylate, magnesium salicylate, or sodium salicylate identified in §§ 343.10(b), (c), (d), (e) and ( f). (A) The labeling states the warning in paragraph (c)(3)(i) of this section plus ‘‘[bullet] the user feels faint, vomits blood, or has bloody or black stools. These are signs of stomach bleeding. [bullet] stomach pain or upset gets worse or lasts [bullet] ringing in the ears or loss of hearing occurs’’. (B) The labeling states the warning in § 201.325(a)(2)(v)(B) plus ‘‘[bullet] is a child with pain of arthritis’’. (C) The labeling states the warning in § 201.325(a)(2)(v)(C) plus ‘‘[bullet] PO 00000 Frm 00043 Fmt 4702 Sfmt 4702 taking a prescription drug for diabetes, gout, or arthritis’’. Dated: November 22, 2006. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E6–21855 Filed 12–19–06; 8:45 am] BILLING CODE 4160–01–S DEPARTMENT OF THE TREASURY Internal Revenue Service 26 CFR Part 1 [REG–136806–06] RIN 1545–BF87 Treatment of Payments in Lieu of Taxes Under Section 141 Internal Revenue Service (IRS), Treasury. AGENCY: Change of location of public hearing. ACTION: SUMMARY: On October 19, 2006, on page 61693 of the Federal Register (71 FR 61693), a notice of proposed rulemaking and notice of public hearing announced that a public hearing concerning applying the private security or payment test for State and local governmental issuers of tax-exempt bonds will be held February 13, 2007 in the auditorium of the New Carrollton Federal Building, 5000 Ellin Road, Lanham, MD 20706. The location of the public hearing has changed. The public hearing will be held in the IRS Auditorium, Internal Revenue Building, 1111 Constitution Avenue, NW., Washington, DC. ADDRESSES: FOR FURTHER INFORMATION CONTACT: Concerning submissions of comments, the hearing, and/or to be placed on the building access list to attend the hearing Kelly Banks, (202) 622–0392 (not a tollfree number). LaNita Van Dyke, Branch Chief, Publications and Regulations, Associate Chief Counsel, Legal Processing Division, (Procedure and Administration). [FR Doc. E6–22017 Filed 12–22–06; 8:45 am] BILLING CODE 4830–01–P E:\FR\FM\26DEP1.SGM 26DEP1

Agencies

[Federal Register Volume 71, Number 247 (Tuesday, December 26, 2006)]
[Proposed Rules]
[Page 77352]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-22017]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF THE TREASURY

Internal Revenue Service

26 CFR Part 1

[REG-136806-06]
RIN 1545-BF87


Treatment of Payments in Lieu of Taxes Under Section 141

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Change of location of public hearing.

-----------------------------------------------------------------------

SUMMARY: On October 19, 2006, on page 61693 of the Federal Register (71 
FR 61693), a notice of proposed rulemaking and notice of public hearing 
announced that a public hearing concerning applying the private 
security or payment test for State and local governmental issuers of 
tax-exempt bonds will be held February 13, 2007 in the auditorium of 
the New Carrollton Federal Building, 5000 Ellin Road, Lanham, MD 20706. 
The location of the public hearing has changed.

ADDRESSES: The public hearing will be held in the IRS Auditorium, 
Internal Revenue Building, 1111 Constitution Avenue, NW., Washington, 
DC.

FOR FURTHER INFORMATION CONTACT: Concerning submissions of comments, 
the hearing, and/or to be placed on the building access list to attend 
the hearing Kelly Banks, (202) 622-0392 (not a toll-free number).

LaNita Van Dyke,
Branch Chief, Publications and Regulations, Associate Chief Counsel, 
Legal Processing Division, (Procedure and Administration).
 [FR Doc. E6-22017 Filed 12-22-06; 8:45 am]
BILLING CODE 4830-01-P